Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Tamsulosin proven safe, effective for ureteral stones

6 days ago

Results of a recent meta-analysis show the efficacy and relative safety of tamsulosin in patients with ureteral stone as a medical expulsive therapy to facilitate stone passage.

Additionally, tamsulosin must be administered selectively in patients with 5–10 mm ureteral stones, according to the authors.

Fifty-six randomized controlled trials (RCTs), involving 9,395 patients, were included. In the observed treatment effect, tamsulosin correlated with a higher rate of stone expulsion (risk ratio [RR], 1.44; 95 percent CI, 1.35–1.55; p<0.01), a shorter stone expulsion time (weighted mean difference [WMD], –0.73; 1.00 to –0.45; p<0.01), and fewer incidences of of ureteral colic (WMD, –0.81; –1.24 to –0.39; p<0.01) and requiring subsequent intervention (RR, 0.68; 0.50–0.93; p=0.017).

The overall incidence of side effects (RR, 1.14; 0.86–1.51; p=0.36) did not differ between patients treated with tamsulosin and those in the control group. Subgroup analysis indicated a significant benefit in the stone expulsion rate for tamsulosin among patients with stones >5 mm (RR, 1.44; 1.22–1.68; p<0.01). However, there was no effect for stones 5 mm (RR, 1.08; 0.99–1.68; p<0.01).

A systematic search of Medline, Embase, Googhle Scholar, Web of Knowledge and Cochrane Central Search Library databases up to June 2018 was performed. Eligible RCTs of the efficacy of tamsulosin in treating ureteral stones were evaluated independently by two reviewers. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system was used to assess the quality of studies. Finally, heterogeneity was explored through subgroup analyses.

“Tamsulosin is widely administered as a medical expulsive therapy to facilitate stone passage in patients with ureteral calculi. Recently several large, multicenter, randomized controlled trials revealed conflicting results, which led to considerable uncertainty about the efficacy of tamsulosin in the management of ureteral stones,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.